Who are Cytalux's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cytalux, Alimta, Flotufolastat (18F), OTL38 for Injection, Mirvetuximab soravtansine plus Bevacizumab, AFOLIA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cytalux.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Cytalux — Competitive Intelligence Brief

Cytalux (Cytalux) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Folate receptor alpha Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cytalux (Cytalux) — Ann & Robert H Lurie Children's Hospital of Chicago.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cytalux TARGET	Cytalux	Ann & Robert H Lurie Children's Hospital of Chicago	marketed		Folate receptor alpha
Cytalux	PAFOLACIANINE	On Target Labs	marketed	Optical Imaging Agent	Folate receptor alpha	2021-01-01
Alimta	pemetrexed	Actavis	marketed	Folate Analog Metabolic Inhibitor	Folate receptor alpha	2004-01-01
Flotufolastat (18F)	Flotufolastat (18F)	Blue Earth Diagnostics	marketed	Folate receptor-targeted PET imaging agent	Folate receptor alpha (FR-α)
OTL38 for Injection	OTL38 for Injection	On Target Laboratories, LLC	phase 3	Antibody-drug conjugate (ADC)	Folate receptor alpha (FRA)
Mirvetuximab soravtansine plus Bevacizumab	Mirvetuximab soravtansine plus Bevacizumab	AbbVie	phase 3	Antibody-drug conjugate (mirvetuximab soravtansine) + monoclonal antibody (bevacizumab)	Folate receptor alpha (FRA) and VEGF
AFOLIA	AFOLIA	Fertility Biotech AG	phase 3		Folate receptor alpha (FRα)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2035-10-28 — Alimta · 9604990 · Compound · US
2036-02-19 — Alimta · 12115164 · Method of Use · US
2036-02-19 — Alimta · 11793813 · Formulation · US

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cytalux — Competitive Intelligence Brief. https://druglandscape.com/ci/cytalux. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab